Effectiveness and Safety of Cinobufacini Combined with Chemotherapy in the Treatment of Colorectal Cancer: A Meta-analysis

Abstract

Abstract: Objective To investigate the efficacy and safety of Cinobufacini combined with chemotherapy in the treatment of colorectal cancer (CRC). Methods By searching the publicly published case-control studies on the combination of Cinobufacini in the treatment of colorectal cancer, RevMan 5.3 analysis software was used for systematic evaluation. Results A total of 10 research data were included. Meta-analysis showed that compared with conventional chemotherapy, the combination of cinobufagin and chemotherapy drugs could significantly improve the chemotherapy effect of patients (P=0.0001), the quality of patients life, KPS score (P<0.00001), and relieve pain (P<0.0003). In addition, a series of adverse reactions caused by chemotherapy were significantly reduced in colorectal patients (P<0.05). Conclusion Cinobufacini combined with chemotherapy has a more significant clinical effect than chemotherapy alone in the treatment of colorectal patients.

Key words: cinobufacini, chemotherapy, colorectal cancer, efficacy, meta analysis

摘要： 目的探讨华蟾素联合化疗治疗结直肠癌（CRC）的疗效和安全性。方法通过检索数据库中公开发表的关于华蟾素联合治疗结直肠癌的病例对照研究,采用RevMan 5.3分析软件进行系统评价。结果共纳入10项研究数据。Meta分析显示,与常规化疗相比,华蟾素与化疗药物联合使用能显著提高患者的化疗效果（P=0.0001）,同时明显改善患者的生活质量,提高KPS评分（P<0.00001）和缓解疼痛（P<0.0003）,化疗引起的一系列不良反应在结直肠患者中明显减轻（P<0.05）。结论华蟾素联合化疗治疗结直肠患者比单纯化疗具有更显著的临床效果。

关键词: 华蟾素, 化疗, 结直肠癌, 疗效, Meta分析

CLC Number:

R735.3

LI Lu, HUANG Yan-jie, ZHENG Ji-ning. Effectiveness and Safety of Cinobufacini Combined with Chemotherapy in the Treatment of Colorectal Cancer: A Meta-analysis[J]. Journal of Chengde Medical University, 2022, 39(2): 91-95.

李璐, 黄艳洁, 郑纪宁. 华蟾素联合化疗治疗结直肠癌的疗效与安全性的系统评价[J]. 承德医学院学报, 2022, 39(2): 91-95.

References

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
[2] Ji Q, Luo YQ, Wang WH, et al.Research advances in traditional Chinese medicine syndromes in cancer patients[J]. J Integr Med, 2016, 14(1): 12-21.
[3] Guo Y, Zou Y, Xu YF, et al.Study on Chinese medicine syndrome of colorectal carcinoma in perioperative period[J]. Chin J Integr Med, 2015, 21(3): 183-187.
[4] 于秀荣,陈钧泽,李慧杰,等. 华蟾素抗肿瘤研究[J]. 中医学报,2019,34(6):1174-1178.
[5] 周晖,章亮,田国燕,等. 华蟾素胶囊辅助治疗晚期结直肠癌效果评价[J]. 中国乡村医药,2014,21(13):9-10.
[6] 韩娜娜. 华蟾素胶囊联合FOLFOX6方案治疗79例晚期直肠癌的临床研究[J]. 北方药学,2019,16(2):89-90.
[7] 李方,李楠. 华蟾素胶囊联合奥沙利铂、替吉奥方案治疗中晚期结直肠癌临床疗效[J]. 临床军医杂志,2016,44(10):1033-1036.
[8] 全斌. 华蟾素胶囊联合化疗方案治疗直肠癌疗效观察[J]. 新中医,2016,48(4):197-199.
[9] 史延江,李赟,赵娜. 华蟾素胶囊联合化疗治疗Ⅲ期结肠癌术后患者的疗效[J]. 中国肿瘤临床与康复,2017,24(9):1078-1081.
[10] 陆屸,陆晓,邵琪,等. 华蟾素胶囊联合化学治疗晚期结直肠癌30例临床研究[J]. 交通医学,2014,28(6):647-648,651.
[11] 刘金鹏,江静,魏辉,等. 华蟾素联合XELOX方案治疗晚期结肠癌的临床疗效观察[J]. 西部医学,2017,29(11):1560-1563.
[12] 董淼. 华蟾素联合化疗治疗晚期结肠癌的临床疗效观察[J]. 中国社区医师,2018,34(13):27-28.
[13] 黄锦林,刘小华. 华蟾素注射液联合化疗治疗复发转移性结直肠癌的临床观察[J]. 临床医学,2012,32(12):56-57.
[14] 东丽,李卉,李刚,等. 华蟾素胶囊联合XELOX方案治疗中晚期结直肠癌临床疗效观察[J]. 海峡药学,2017,29(10):169-171.
[15] Huang CH, Chang HP, Su SY, et al.Traditional Chinese medicine is associated with a decreased risk of heart failure in breast cancer patients receiving doxorubicin treatment[J]. J Ethnopharmacol, 2018, 229: 15-21.
[16] Ma X, Hu M,Wang H, et al.Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance[J]. Eur J Med Chem, 2018, 159: 381-392.
[17] Cheng L, Chen YZ, Peng Y, et al.Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells[J]. Tumour Biol, 2015, 36(8): 5763-5771.
[18] Li QW, Sun T, Hu KW.Research progress on anti-tumor mechanism of cinobufagin[J]. China J Tradit Chin Med Pharm, 2010, 25(12): 2075-2078.
[19] Wang J, Cai H, Liu Q, et al.Cinobufacini Inhibits Colon Cancer Invasion and Metastasis via Suppressing Wnt/β-Catenin Signaling Pathway and EMT[J]. Am J Chin Med, 2020, 48(3): 703-718.
[20] Ma L, Song B, Jin H, et al.Cinobufacini induced MDA-MB-231 cell apoptosis-associated cell cycle arrest and cytoskeleton function[J]. Bioorg Med Chem Lett, 2012, 22(3): 1459-1463.
[21] Qi F, Li A, Inagaki Y, et al.Induction of apoptosis by cinobufacini preparation through mitochondria- and Fas-mediated caspase-dependent pathways in human hepatocellular carcinoma cells[J]. Food Chem Toxicol, 2012, 50(2): 295-302.